423 related articles for article (PubMed ID: 36821822)
1. E3 Ligases Meet Their Match: Fragment-Based Approaches to Discover New E3 Ligands and to Unravel E3 Biology.
Michaelides IN; Collie GW
J Med Chem; 2023 Mar; 66(5):3173-3194. PubMed ID: 36821822
[TBL] [Abstract][Full Text] [Related]
2. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
Ishida T; Ciulli A
SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
[TBL] [Abstract][Full Text] [Related]
3. Discovery of E3 Ligase Ligands for Target Protein Degradation.
Lee J; Lee Y; Jung YM; Park JH; Yoo HS; Park J
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235052
[TBL] [Abstract][Full Text] [Related]
4. Covalent fragment-based ligand screening approaches for identification of novel ubiquitin proteasome system modulators.
Rothweiler EM; Brennan PE; Huber KVM
Biol Chem; 2022 Mar; 403(4):391-402. PubMed ID: 35191283
[TBL] [Abstract][Full Text] [Related]
5. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
Setia N; Almuqdadi HTA; Abid M
Eur J Med Chem; 2024 Feb; 265():116041. PubMed ID: 38199162
[TBL] [Abstract][Full Text] [Related]
6. The rise of covalent proteolysis targeting chimeras.
Gabizon R; London N
Curr Opin Chem Biol; 2021 Jun; 62():24-33. PubMed ID: 33549806
[TBL] [Abstract][Full Text] [Related]
7. Application of AlphaFold models in evaluating ligandable cysteines across E3 ligases.
Koldenhof P; Bemelmans MP; Ghosh B; Damm-Ganamet KL; van Vlijmen HWT; Pande V
Proteins; 2024 Jul; 92(7):819-829. PubMed ID: 38337153
[TBL] [Abstract][Full Text] [Related]
8. Driving E3 Ligase Substrate Specificity for Targeted Protein Degradation: Lessons from Nature and the Laboratory.
Cowan AD; Ciulli A
Annu Rev Biochem; 2022 Jun; 91():295-319. PubMed ID: 35320687
[TBL] [Abstract][Full Text] [Related]
9. TAC-tics for Leveraging Proximity Biology in Drug Discovery.
Nalawansha DA; Mangano K; den Besten W; Potts PR
Chembiochem; 2024 Feb; 25(4):e202300712. PubMed ID: 38015747
[TBL] [Abstract][Full Text] [Related]
10. Building ubiquitination machineries: E3 ligase multi-subunit assembly and substrate targeting by PROTACs and molecular glues.
Ramachandran S; Ciulli A
Curr Opin Struct Biol; 2021 Apr; 67():110-119. PubMed ID: 33271439
[TBL] [Abstract][Full Text] [Related]
11. Expanding the ligand spaces for E3 ligases for the design of protein degraders.
Shah Zaib Saleem R; Schwalm MP; Knapp S
Bioorg Med Chem; 2024 May; 105():117718. PubMed ID: 38621319
[TBL] [Abstract][Full Text] [Related]
12. Evaluating Ligands for Ubiquitin Ligases Using Affinity Beads.
Dobrodziej J; Dong H; Zimmermann K; Hickey CM
Methods Mol Biol; 2021; 2365():59-75. PubMed ID: 34432239
[TBL] [Abstract][Full Text] [Related]
13. E3 ligase ligand chemistries: from building blocks to protein degraders.
Sosič I; Bricelj A; Steinebach C
Chem Soc Rev; 2022 May; 51(9):3487-3534. PubMed ID: 35393989
[TBL] [Abstract][Full Text] [Related]
14. Assessing Different E3 Ligases for Small Molecule Induced Protein Ubiquitination and Degradation.
Ottis P; Toure M; Cromm PM; Ko E; Gustafson JL; Crews CM
ACS Chem Biol; 2017 Oct; 12(10):2570-2578. PubMed ID: 28767222
[TBL] [Abstract][Full Text] [Related]
15. High throughput E3 ligase degron binding assays for novel PROTAC ligand discovery.
Guenette RG; Potts PR
Methods Enzymol; 2023; 681():23-39. PubMed ID: 36764759
[TBL] [Abstract][Full Text] [Related]
16. Exploration of Aberrant E3 Ligases Implicated in Alzheimer's Disease and Development of Chemical Tools to Modulate Their Function.
Potjewyd FM; Axtman AD
Front Cell Neurosci; 2021; 15():768655. PubMed ID: 34867205
[TBL] [Abstract][Full Text] [Related]
17. Modeling the CRL4A ligase complex to predict target protein ubiquitination induced by cereblon-recruiting PROTACs.
Bai N; Riching KM; Makaju A; Wu H; Acker TM; Ou SC; Zhang Y; Shen X; Bulloch DN; Rui H; Gibson BW; Daniels DL; Urh M; Rock BM; Humphreys SC
J Biol Chem; 2022 Apr; 298(4):101653. PubMed ID: 35101445
[TBL] [Abstract][Full Text] [Related]
18. PROTACs: An Emerging Therapeutic Modality in Precision Medicine.
Nalawansha DA; Crews CM
Cell Chem Biol; 2020 Aug; 27(8):998-1014. PubMed ID: 32795419
[TBL] [Abstract][Full Text] [Related]
19. N/C-degron pathways and inhibitor development for PROTAC applications.
Wu Z; Huang Y; Liu K; Min J
Biochim Biophys Acta Gene Regul Mech; 2024 Mar; 1867(1):194952. PubMed ID: 37263341
[TBL] [Abstract][Full Text] [Related]
20. ELIOT: A platform to navigate the E3 pocketome and aid the design of new PROTACs.
Palomba T; Baroni M; Cross S; Cruciani G; Siragusa L
Chem Biol Drug Des; 2023 Jan; 101(1):69-86. PubMed ID: 35857806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
